Australia  

Trials show progress on COVID-19 immunity, vaccines

Video Credit: Reuters Studio - Duration: 02:09s - Published
Trials show progress on COVID-19 immunity, vaccines

Trials show progress on COVID-19 immunity, vaccines

Two studies on monkeys published Wednesday offer some of the first scientific evidence that surviving COVID-19 may result in immunity from reinfection.

In a separate published study Inovio Pharmaceuticals said its experimental vaccine produced positive results in animal trials.

Conway G.

Gittens has more.

0
shares
ShareTweetSavePostSend
 

There are promising signs in the race to come up with a COVID-19 vaccine and to understand if humans can be immune after recovering from infection.

Two studies published on Wednesday offered the first scientific evidence that reinfection may not be possible.

In one study, monkeys who were infected by researchers with the novel coronavirus and recovered did not get sick again once exposed to the virus.

In the second study, 25 monkeys were given prototype vaccines and 10 other animals were not; after both groups were exposed to a coronavirus related to SARS, all of the animals not vaccinated came down with the virus, while the vaccinated monkeys saw some measure of protection.

In fact, 8 of the 25 monkeys were totally protected.

While both results were promising and suggest the search for a vaccine is on the right track, scientists caution that they still don't prove humans can develop immunity and if they do - how long it lasts.

There are currently no approved treatments or vaccines for COVID-19 and experts predict a safe and effective vaccine could take up to 18 months to develop.

But there is a race to shorten that window.

Inovio Pharmaceuticals, a U.S.-based immunotherapy company, announced Wednesday its experimental treatment produced protective antibodies and immune system responses in mice and guinea pigs.

Its vaccine builds on a potential treatment Inovio was already working on for a different, but related coronavirus that causes Middle East Respiratory Syndrome.

Both treatments are made using newer technology that focuses on specific genes.

Trials on 40 humans began in April and preliminary results are expected next month.

Approval would then be needed from the Food and Drug Administration to conduct more-advanced human trials.

That could happen as early as July or August.

Last week, President Trump announced the U.S. government would invest in all potential vaccines in hopes of getting a treatment on the market by the end of this year.




💡 One News Page Knowledge: Other News Mentions

Coronavirus disease 2019 Coronavirus disease 2019 Infectious respiratory disease caused by severe acute respiratory syndrome coronavirus 2

Couple visits Himachal with fake COVID negative certificates, case registered [Video]

Couple visits Himachal with fake COVID negative certificates, case registered

A Delhi couple was caught visiting Dharamshala by producing fake COVID-19 negative certificates. While speaking to ANI in Himachal Pradesh's Dharamshala on July 09, the Superintendent of Police (SP) of Kangra, Vimukt Ranjan said, "We have sent them to institutional quarantine center, they will be tested today. Case has been registered against them. Action will be taken according to their report." "They had first produced antibody test report which said it is not comprehensive COVID-19 negative test. So we denied them entry. Yesterday (July 08), they returned with RT-PCR report on Ram Manohar Lohia (RML) hospital's letter-head. We cross-verified it with RML and got to know it is fake, not issued by RML," Kangra SP added.

Credit: ANI    Duration: 01:57Published
COVID-19: 'Safety of students our prime concern', says UGC Secy on examinations [Video]

COVID-19: 'Safety of students our prime concern', says UGC Secy on examinations

While speaking to ANI in the national capital on July 09, the Secretary of University Grants Commission (UGC), Professor Rajnish Jain spoke on importance of fresh guidelines for academic calendar and examinations. He said, "Conducting final year examinations for graduation or post-graduation courses is very important, and the safety of students is our prime concern."

Credit: ANI    Duration: 02:18Published
COVID-19: India's cases, fatalities per million among lowest in world, says Health Ministry [Video]

COVID-19: India's cases, fatalities per million among lowest in world, says Health Ministry

In media brief held on July 09, OSD of Ministry of Health, Rajesh Bhushan said that despite a population of 1.3 billion people, India has been able to manage COVID-19 relatively well. Bhushan said, "We are the second-most populous country of the world. Despite a population of 1.3 billion people, India has been able to manage COVID-19 relatively well. If you look at cases per million population it still remains amongst lowest in the world. Today, we have 538 cases per million population, it's as per WHO situation report. Case per million population in some countries are at least 16-17 times more than what it is in India. We have 15 deaths per million population whereas we have countries where it is 40 times as much." He further said, "When we talk of case load of COVID-19 in India, it is 2,69,000 people. This tells us that at the end of the day we have managed a situation where our health care infrastructure is not unduly burdened and is not creaking due to the pressure."

Credit: ANI    Duration: 02:42Published
15th meeting of India-EU summit will be held in virtual mode on July 15: MEA [Video]

15th meeting of India-EU summit will be held in virtual mode on July 15: MEA

The official spokesperson of Ministry of External Affairs (MEA), Anurag Srivastava informed that 15th meeting of India-EU summit will be held in virtual mode on 15 July. Anurag Srivastava said, "The 15th meeting of India-EU summit will be held in virtual mode on 15 July. It will be co-chaired by Prime Minister, President of European Council and President of European Commission. The summit will review India-EU cooperation, also expected to discuss developments around COVID."

Credit: ANI    Duration: 01:00Published

Inovio Pharmaceuticals Inovio Pharmaceuticals American biotechnology company


Donald Trump Donald Trump 45th president of the United States

Ex-Trump lawyer behind bars again [Video]

Ex-Trump lawyer behind bars again

[NFA] Michael Cohen, U.S. President Donald Trump's former personal attorney, was taken to a federal jail on Thursday after refusing to agree to a gag order as a condition of serving his criminal sentence under home confinement, Cohen's lawyer said. Freddie Joyner reports.

Credit: Reuters Studio    Duration: 01:22Published
Trump says SCOTUS rulings part of 'witch hunt' [Video]

Trump says SCOTUS rulings part of 'witch hunt'

U.S. President Donald Trump on Thursday described two U.S. Supreme Court rulings concerning his financial records as a "hoax" and a "political witch hunt - the likes of which nobody's ever seen before."

Credit: Reuters Studio    Duration: 01:09Published
Biden challenges Trump 'talk,' unveils economic plan [Video]

Biden challenges Trump 'talk,' unveils economic plan

Democratic presidential candidate Joe Biden on Thursday proposed boosting manufacturing and innovation by spending $700 billion in his first four-year term to procure more American-made goods, and invest in research and development.

Credit: Reuters Studio    Duration: 02:03Published
U.S. finalizing federal ban on Chinese tech parts [Video]

U.S. finalizing federal ban on Chinese tech parts

The Trump administration plans to finalize regulations this week that will bar the U.S. government from buying goods or services from any company that uses products from five Chinese companies including Huawei, Hikvision and Dahua, a U.S. official told Reuters exclusively. Conway G. Gittens reports.

Credit: Reuters Studio    Duration: 01:19Published

Middle East respiratory syndrome Middle East respiratory syndrome Viral respiratory infection

Study: 'Cytokine Storms' Key To Escalation Of COVID-19 Cases From Mild To Severe [Video]

Study: 'Cytokine Storms' Key To Escalation Of COVID-19 Cases From Mild To Severe

A new review of research reveals "cytokine storms" are key in causing coronavirus cases to go from mild to severe. According to Business Insider, the so-called 'storms' are an overly aggressive reaction from the patient's own immune system. The reaction prompts white blood cells to attack healthy lung tissue, resulting in life-threatening damage. This response was also characteristic of patients who died of H1N1, SARS, MERS, and the 1918 flu.

Credit: Wochit News    Duration: 00:38Published

Food and Drug Administration Food and Drug Administration Agency of the United States Department of Health and Human Services

Too soon to say if RNC will be safe -U.S. official [Video]

Too soon to say if RNC will be safe -U.S. official

Stephen Hahn, the Food and Drug Administration commissioner, said on Sunday it was "too early to tell" if it would be safe for people to attend August's Republican National Convention in Jacksonville, Florida. This report produced by Chris Dignam.

Credit: Reuters Studio    Duration: 01:43Published
FDA Commissioner Won't Confirm Or Deny Trump's Unfounded COVID-19 Claim [Video]

FDA Commissioner Won't Confirm Or Deny Trump's Unfounded COVID-19 Claim

The commissioner of the US Food and Drug Administration on Sunday didn't defend a claim recently made by President Donald Trump. But according to CNN, he didn't support it, either. Dr. Stephen Hahn is a member of the White House coronavirus task force. At a White House Independence Day event on Saturday, Trump made an unfounded claim that 99% of coronavirus cases are 'totally harmless.' In a CNN interview with Dana Bash on Sunday, Dr.

Credit: Wochit News    Duration: 00:45Published
Gilead to Charge $3,120 Per Patient for Typical Covid-19 Treatment [Video]

Gilead to Charge $3,120 Per Patient for Typical Covid-19 Treatment

Gilead is the pharmaceutical company behind a drug that’s been approved for COVID emergencies. The FDA officially announced the medicine could be used in treating COVID-19 patients. Gilead has now announced the drug will cost $3,120 per typical treatment course for insured individuals. Research has indicated the drug could cut the recovery time for hospitalized COVID-19 patients. It could shorten satsy by several days, reports Gizmodo.

Credit: Wochit News    Duration: 00:35Published
Former FDA head says 'exponential' rise in COVID-19 possible [Video]

Former FDA head says 'exponential' rise in COVID-19 possible

Former Food and Drug Administration Commissioner Scott Gottlieb on Sunday warned that some U.S. states, including Texas, Florida and Arizona, could start to see an 'exponential' rise in COVID-19 cases this coming week. This report produced by Yahaira Jacquez.

Credit: Reuters - Politics    Duration: 01:40Published

You Might Like


Tweets about this

drparitoshbhatt

Paritosh Bhatt🇮🇳 RT @rajivvasudevan: "In 3 large studies, 2 in people exposed to the virus & at risk of infection, & 1 in severely ill patients, show no ben… 4 days ago

rajivvasudevan

Rajiv Vasudevan "In 3 large studies, 2 in people exposed to the virus & at risk of infection, & 1 in severely ill patients, show no… https://t.co/cWvyNezpub 4 days ago

mmekonen1

Mesfin Mekonen Remdesivir is the first drug to show improvement in COVID-19 in human trials, and its progress in clinical studies… https://t.co/z3rpx7Vvh0 6 days ago


Related videos from verified sources

U.S. Gives $1.6B to Novavax to Deliver 100M Doses of Potential COVID-19 Vaccine by 2021 [Video]

U.S. Gives $1.6B to Novavax to Deliver 100M Doses of Potential COVID-19 Vaccine by 2021

At $1.6 billion, Novavax receives the largest amount the Trump administration has awarded to a company to manufacture millions of doses of a coronavirus vaccine set to be delivered by January...

Credit: Veuer     Duration: 01:20Published
Covaxin trials to begin soon in India, 1000 participants to get shots| Oneindia News [Video]

Covaxin trials to begin soon in India, 1000 participants to get shots| Oneindia News

India's race to find a vaccine is heating up. The indigenously made Covaxin which has been cleared for Phase-I and Phase-II trials by the Drug Controller General of India, will be tested on more than..

Credit: Oneindia     Duration: 01:19Published
Covid vaccine race| India puts 2 to human trials: Where do we stand? |Oneindia News [Video]

Covid vaccine race| India puts 2 to human trials: Where do we stand? |Oneindia News

India's Covaxin has entered clinical trials while the Drug controller Genral of India gave the nod for another vaccine by Zydus Cadila for phase I and II human trials. ICMR has asked Bharat Biotech to..

Credit: Oneindia     Duration: 01:30Published